Related Experiment Video
Updated: Nov 7, 2025
10:35
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
18.5K
Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies
Jhalak Dholakia1, Carly Scalise1, Rebecca C Arend1
1Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Cancers
|April 30, 2021
Summary
Developing novel treatments for gynecologic malignancies requires better preclinical models for immunotherapy research. This review details models like murine systems and 3D tissues to improve translational efficiency and patient outcomes.
Area of Science:
- Gynecologic Oncology
- Immunotherapy
- Translational Research
Background:
- Gynecologic malignancies show increasing incidence but stagnant clinical outcomes.
- Immunotherapy targeting PD-1/CTLA-4 axes and Wnt pathway shows modest success in these cancers.
- Novel treatment strategies are urgently needed.
Purpose of the Study:
- To review and contextualize preclinical models for gynecologic oncology immunotherapy research.
- To inform the design and implementation of translational research models.
- To enhance the efficiency and translational value of preclinical findings.
Main Methods:
- Comprehensive review of existing preclinical models.
- Analysis of murine models, in vitro assays, and 3D human-tissue-based systems.
- Evaluation of benefits and limitations of each model type.
Main Results:
- Preclinical models are crucial for advancing gynecologic oncology immunotherapy.
- Different models offer unique advantages and disadvantages for translational research.
- Optimized model selection and design are key to successful translation.
Conclusions:
- Improved preclinical models are essential for developing effective immunotherapies for gynecologic cancers.
- Strategic use of validated models will accelerate the discovery of novel treatments.
- Enhancing translational efficiency promises better patient outcomes in gynecologic oncology.
